June 9, 2016
Cambridge, MA

Solid Grows Therapeutic Pipeline with New Disease Modifying Therapy Candidate

Solid is committed to building a robust pipeline of candidates that target the multiple facets of Duchenne muscular dystrophy. It is with this goal in mind that we are excited to announce a new collaboration with Dr. Elizabeth McNally, M.D, Ph.D., of Northwestern University to develop a novel anti-fibrotic candidate with the potential to support muscle repair.

Muscular dystrophy is characterized by the replacement of muscle with non-functional fibrotic tissue, which is caused by continuous inflammation and muscle degeneration. The goal of this program is to target a known mediator of fibrosis, or TGF-b,  and inhibit its activity. We believe that this goal can be accomplished by modulating a protein known as the latent TGF-b binding protein 4 (LTBP4).

LTBP4 has been identified as a genetic modifier of Duchenne muscular dystrophy and has been associated with a delayed loss of ambulation. If successful, we believe that a therapy utilizing this novel pathway has the potential to reduce fibrosis in Duchenne muscular dystrophy patients and slow functional decline.

The LTBP4 candidate is currently in early discovery.  Solid is excited to work with Dr. McNally and her team to unlock the potential of LTBP4 and hopefully begin to move it through development

View Our Pipeline

Related news

Jun26

Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President
Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities

Jun18

We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.

Jun18

- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway

- Conference Call Scheduled for Today at 8:30 A.M. ET

May19

- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -

- Company Continues to Advance Gene Therapy Portfolio -

May10
Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial
Apr18

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -

Mar29

Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.

Mar14

Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.

Feb28

Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day

Nov30

Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.

Pages

More information about Solid?

Please subscribe to receive our latest news